Dr. Hiroshi Maeda, M.D., Ph.D., Director, BioDymanics Research Foundation, Professor Emeritus Kumamoto University Medical School, Senior Invited Professor of Osaka University Medical School, Special Appointee Professor, Tohoku University is a world renowned expert in macromolecular therapeutics for cancer treatment. He was successful in creating the world first polymeric drug, SMANCS (1979), which was approved for treatment of hepatoma in Japan in 1993. Along this line he discovered the concept of the EPR (enhanced permeability and retention) effect of macromolecular drugs, a unique mechanism responsible for solid tumor selective targeting of polymeric drugs. More recently, he has developed a numbers of macromolecular drugs with very high tumor selective accumulation. This concept is also applicable to protein drugs including IgG, micellar and liposomal drugs, gene complexed nanoparticles, and even oncolytic virus particles.
He received MS degree from the University of California at Davis, where he was a Fulbright Student, and Ph.D. and M.D. from Tohoku University in Sendai, Japan. He has more than 450 papers published in international reputed journals.
He received the Princess Takamatsu Award in Cancer Research, Dr. Tomizo Yoshida Award the highest award from Japan Cancer Association in 2011, and other awards from various societies in USA, Germany, UK and Japan as shown in separate pages. He was also one of the top five awardee of 2016 Thomson Reuter’s Web-of-Science Citation Laureates in Chemistry in the world. Honorary Citizen of State of Oklahoma and Honorary Mayor of San Antonio, Texas.